A monoclonal antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2), that mimics TRAIL-mediated activation of the receptor and induces cell death, has been developed and is currently in a phase I clinical trial in combination with bortezomib or vorinostat for the treatment of various types of lymphoma. Here, TNFSF10 is linked to lymphoma.